Peter Meyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Meyer has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Christina Schmitt
Department of Dermatology, University Hospital, Tuebingen
2 shared publications- Claus Garbe
Centre for Dermatooncology, Department of Dermatology Eberhard Karls University Tuebingen Germany
2 shared publications Melanie Barbara Boettger
2 shared publicationsRuediger Klaes
Institute of Human Genetics, University Hospital, Heidelberg
2 shared publications- Alexander Semmler
University Zurich, Department of Neurology, Zurich, Switzerland
1 shared publication Barbara Burwinkel
1 shared publication
Latest Publications
- Open Access
- 24 October 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 439
Haplotype analysis of the 5,10-methylenetetrahydrofolate reductase (MTHFR) c.1298A>C (E429A) polymorphism
The polymorphism 5,10-methylenetetrahydrofolate reductase (MTHFR) c.1298A>C is associated with various diseases. 45 DNA samples homozygous for the A allele and 40 DNA probes homozygous for the C allele were taken from healthy German subjects of white Caucasian origin to analyze the haplotype of the two MTHFR c.1298A>C alleles. Samples were genotyped for the polymorphism MTHFR c.677C>T and for the silent polymorphisms MTHFR c.129C>T, IVS2 533 G>A, c.1068C>T and IVS10 262C>G.
- 24 October 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 439
Open AccessHaplotype analysis of the 5,10-methylenetetrahydrofolate reductase (MTHFR) c.1298A>C (E429A) polymorphism
The polymorphism 5,10-methylenetetrahydrofolate reductase (MTHFR) c.1298A>C is associated with various diseases. 45 DNA samples homozygous for the A allele and 40 DNA probes homozygous for the C allele were taken from healthy German subjects of white Caucasian origin to analyze the haplotype of the two MTHFR c.1298A>C alleles. Samples were genotyped for the polymorphism MTHFR c.677C>T and for the silent polymorphisms MTHFR c.129C>T, IVS2 533 G>A, c.1068C>T and IVS10 262C>G.
- 1 April 2007
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 17 (2) , 109-116
Molecular genetic analysis of NBS1 in German melanoma patients
The aim of this study was to investigate the role of NBS1 in the pathogenesis of malignant melanoma of the skin. To exclude the common 657del5 founder mutation, a total of 376 melanoma patients from Southern Germany were analyzed for sequence alterations in exon 6 of NBS1 by direct sequencing. Analyses revealed one 657del5 mutation and three nonsynonymous sequence variations in exon 6 of NBS1 (V210F, R215W, and F222L). Analysis of an additional sample of 629 melanoma patients and 604 controls revealed no F222L mutation, indicating that this newly identified sequence alteration is not a common polymorphism. In a case–control association study including 632 melanoma patients and 615 cancer-free control participants from Southern Germany, three publicly known single nucleotide polymorphisms located in the NBS1 gene region were analyzed. No significant associations between single nucleotide polymorphisms (rs9995, rs867185 and rs1063045) or referring calculated haplotypes and melanoma risk were identified. These results suggest that NBS1 does not play a major role in predisposition to melanoma in the Southern German population but that alterations of this gene might contribute to the risk of this cancer.
- 1 April 2007
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 17 (2) , 109-116
Molecular genetic analysis of NBS1 in German melanoma patients
The aim of this study was to investigate the role of NBS1 in the pathogenesis of malignant melanoma of the skin. To exclude the common 657del5 founder mutation, a total of 376 melanoma patients from Southern Germany were analyzed for sequence alterations in exon 6 of NBS1 by direct sequencing. Analyses revealed one 657del5 mutation and three nonsynonymous sequence variations in exon 6 of NBS1 (V210F, R215W, and F222L). Analysis of an additional sample of 629 melanoma patients and 604 controls revealed no F222L mutation, indicating that this newly identified sequence alteration is not a common polymorphism. In a case–control association study including 632 melanoma patients and 615 cancer-free control participants from Southern Germany, three publicly known single nucleotide polymorphisms located in the NBS1 gene region were analyzed. No significant associations between single nucleotide polymorphisms (rs9995, rs867185 and rs1063045) or referring calculated haplotypes and melanoma risk were identified. These results suggest that NBS1 does not play a major role in predisposition to melanoma in the Southern German population but that alterations of this gene might contribute to the risk of this cancer.
- Open Access
- 1 January 2007
- Published by Sakun Publishing House in Journal of Carcinogenesis
- Vol. 6 (1) , 14
The association between paternal prostate cancer and type 2 diabetes
J Carcinog, Official publication of Carcenogenesis Press
- 1 January 2007
- Published by Sakun Publishing House in Journal of Carcinogenesis
- Vol. 6 (1) , 14
Open AccessThe association between paternal prostate cancer and type 2 diabetes
J Carcinog, Official publication of Carcenogenesis Press
- Open Access
- 14 August 2003
- Published by Hindawi Limited in Human Mutation
- Vol. 22 (3) , 259
Twenty-three novelBRCA1 andBRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany
BRCA1 and BRCA2 germline mutations cause a substantially increased life time risk of both breast and ovarian cancer. Mutational screening of these genes by means of Denaturing High Performance Liquid Chromatography (DHPLC) in breast and/or ovarian cancer-prone families from Southern Germany revealed 15 novel BRCA1 and 8 novel BRCA2 sequence variants. Predictions on the BRCA1/BRCA2 protein functions lead to the identification of 11 novel deleterious cancer predisposing mutations. Mutation types and their functional relevances are discussed. Our data contribute to phenotype-genotype correlation studies and to the characterisation of the mutation spectrum of BRCA1/BRCA2.
- 14 August 2003
- Published by Hindawi Limited in Human Mutation
- Vol. 22 (3) , 259
Open AccessTwenty-three novelBRCA1 andBRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany
BRCA1 and BRCA2 germline mutations cause a substantially increased life time risk of both breast and ovarian cancer. Mutational screening of these genes by means of Denaturing High Performance Liquid Chromatography (DHPLC) in breast and/or ovarian cancer-prone families from Southern Germany revealed 15 novel BRCA1 and 8 novel BRCA2 sequence variants. Predictions on the BRCA1/BRCA2 protein functions lead to the identification of 11 novel deleterious cancer predisposing mutations. Mutation types and their functional relevances are discussed. Our data contribute to phenotype-genotype correlation studies and to the characterisation of the mutation spectrum of BRCA1/BRCA2.
- Open Access
- 2 June 2003
- Published by Wiley in International Journal of Cancer
- Vol. 106 (1) , 78-80
Exclusion of BRAFV599E as a melanoma susceptibility mutation
Very recently, BRAF mutations were found in about 2/3 of malignant melanomas and at lower frequencies in other human cancers. The BRAF gene codes for a protein in the mitogen‐activated protein kinase (MAPK) pathway. All mutations identified to date are within the kinase domain, with a single missense mutation (V599E) accounting for 80%. We investigated the hypothesis that this common somatic BRAF mutation (V599E) would contribute to melanoma predisposition in familial and polygenic malignant melanoma if occuring as a germ‐line mutation. We performed comprehensive mutational screening of exon 15 of BRAF using DHPLC (denaturing high‐performance liquid chromatography) and DNA sequencing techniques. No V599E mutation could be detected in 172 melanoma patients comprising 46 familial cases, 21 multiple melanoma patients and 106 cases with at least one first‐degree relative suffering from other cancers. We therefore conclude that the common somatic BRAF mutation V599E does not contribute to polygenic and familial melanoma predisposition.
- 2 June 2003
- Published by Wiley in International Journal of Cancer
- Vol. 106 (1) , 78-80
Open AccessExclusion of BRAFV599E as a melanoma susceptibility mutation
Very recently, BRAF mutations were found in about 2/3 of malignant melanomas and at lower frequencies in other human cancers. The BRAF gene codes for a protein in the mitogen‐activated protein kinase (MAPK) pathway. All mutations identified to date are within the kinase domain, with a single missense mutation (V599E) accounting for 80%. We investigated the hypothesis that this common somatic BRAF mutation (V599E) would contribute to melanoma predisposition in familial and polygenic malignant melanoma if occuring as a germ‐line mutation. We performed comprehensive mutational screening of exon 15 of BRAF using DHPLC (denaturing high‐performance liquid chromatography) and DNA sequencing techniques. No V599E mutation could be detected in 172 melanoma patients comprising 46 familial cases, 21 multiple melanoma patients and 106 cases with at least one first‐degree relative suffering from other cancers. We therefore conclude that the common somatic BRAF mutation V599E does not contribute to polygenic and familial melanoma predisposition.
- Open Access
- 1 January 2003
- Published by Sakun Publishing House in Journal of Carcinogenesis
- Vol. 2 (1) , 7
Polymorphisms of the BRAF gene predispose males to malignant melanoma
J Carcinog, Official publication of Carcenogenesis Press
- 1 January 2003
- Published by Sakun Publishing House in Journal of Carcinogenesis
- Vol. 2 (1) , 7
Open AccessPolymorphisms of the BRAF gene predispose males to malignant melanoma
J Carcinog, Official publication of Carcenogenesis Press